NEUROBO PHARMACEUTICALS INC (NRBO)       15.36  -0.18 (-1.16%)

15.36  -0.18 (-1.16%)

US64132R2067 - Common Stock


Fundamental Rating

2

Taking everything into account, NRBO scores 2 out of 10 in our fundamental rating. NRBO was compared to 638 industry peers in the Biotechnology industry. NRBO scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. NRBO has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

1

NRBO has a Piotroski-F score of 4.00. This indicates an average health and profitability for NRBO.
NRBO has negative profitability rations, so we won't be analyzing them here.

NRBO's Return On Assets of -141.01% is worse than the rest of the industry. The industry average Return On Assets is -41.07%. 91% of the industry peers have a better Return On Assets.
VS Industry

ROA (-141.01%) VS Industry: 9% outperformed.

-1,441.42
115.38

Valuation

Valuation Rating

1

With a price book ratio of 1.55, NRBO is valued correctly.
When comparing the price book ratio of NRBO to the average industry price book ratio of 1.63, NRBO is valued in line with its industry peers.

The Price/Earnings Ratio is negative for NRBO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRBO. No positive earnings are expected for the next year.
VS Industry

Price/Book (1.55) VS Industry: 51% outperformed.

169.52
0.08

Growth

Growth Rating

3

Based on estimates for the next 5 years, NRBO will show a very strong growth in Earnings Per Share. The EPS will grow by 25.17% on average per year.

NRBO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -146.22%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -146.22% 96.52% 40.12% 25.17% N/A
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

4

NRBO has a Current Ratio of 8.07. This indicates that NRBO is financially healthy and has no problem in meeting its short term obligations.
NRBO has a Quick Ratio of 8.07. This indicates that NRBO is financially healthy and has no problem in meeting its short term obligations.
NRBO has a Current Ratio comparable to the industry average, which is at 6.52.
NRBO has a Quick Ratio comparable to the industry average, which is at 6.48.

The Debt to Equity ratio of NRBO is in line with the industry averages.
The Piotroski-F score of NRBO is 4.00. This is a neutral score and indicates average health and profitability for NRBO.
Based on the Altman-Z score of -9.19, we must say that NRBO is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.02, NRBO is in worse financial state than most of its industry peers. 85% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (0) VS Industry: 43% outperformed.

18.24
0.00

Quick Ratio (8.07) VS Industry: 59% outperformed.

0.03
399.16

Current Ratio (8.07) VS Industry: 58% outperformed.

0.08
401.12

Altman-Z (-9.19) VS Industry: 15% outperformed.

-1,821.48
293.92

Dividend

Dividend Rating

0

No dividends for NRBO!.

NRBO Daily chart

NEUROBO PHARMACEUTICALS INC15.36

NASDAQ:NRBO (9/26/2022, 10:50:37 AM)-0.18 (-1.16%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-15 2022-08-15 Earnings (Next) 11-14 2022-11-14
Ins Owners 20.7% Inst Owners 137.83%
Market Cap 13.65M Analysts 82.86
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 1.55
EV/EBITDA -0.35
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -146.22% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 29.86%
EPS Next Y 96.52% EPS Next 2Y 40.12%
EPS Next 3Y 25.17% EPS Next 5Y N/A
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 8.07 Quick Ratio 8.07
Altman-Z -9.19 F-Score 4
Debt/Equity 0
Profitability
ROA -141.01% ROE N/A
ROIC N/A ROICg N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA